GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

International drug giant GSK plc is moving its vaccine R&D and infectious disease teams to Cambridge from Maryland, and plans to expand its footprint here.

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

Clinical-stage biotechnology company Vaxxas has appointed three global vaccine experts as advisors as it progresses its ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

Learn more about how GSK is harnessing the power of technology to improve outcomes for people with cancer.